87/100BGilead Sciences stock forecast 2026–2030What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for Gilead Sciences is 165.38, 0.9% below the current price of 166.87. Their targets range from 126.00 to 196.00.
Of the 16 firms that rated Gilead Sciences in the past 12 months, 13 rate it buy or strong buy, 3 hold and 0 sell or strong sell (each firm at its latest rating): a Strong buy consensus.
Analysts' 1-year price targets range from 126.00 to 196.00, with an average of 165.38.
| Buy | 13 | |
| Hold | 3 | |
| Sell | 0 |
12-month price target
| Highest target | 196.00 |
| Average target | 165.38 |
| Lowest target | 126.00 |
| Current price | 166.87 |
Gilead Sciences price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their Gilead Sciences price target and rating?
How analysts rate Gilead Sciences, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
13 of 16 firms rate it buy now, against 14 of 18 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Gilead Sciences analyst upgrades, downgrades and price targets
The latest rating change came on 21 July 2026, when Leerink Partners downgraded Gilead Sciences from Outperform to Market Perform. The most recent new target came from Jefferies on 4 November 2026: 196.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 4 Nov 2026 | Jefferies Akash Tewari | — | 185.00 → 196.00 | +5.9% | 167.47 |
| 2 Nov 2026 | Bernstein Courtney Breen | — | 160.00 → 175.00 | +9.4% | 167.33 |
| 30 Oct 2026 | UBS Michael Yee | Reiterated · Buy | 175.00 → 195.00 | +11.4% | 170.95 |
| 30 Oct 2026 | Needham | Reiterated · Buy | 170.00 → 175.00 | +2.9% | 165.61 |
| 30 Oct 2026 | BMO Capital Evan David Seigerman | — | 160.00 → 184.00 | +15.0% | 165.61 |
| 23 Oct 2026 | Jefferies Akash Tewari | — | 180.00 → 185.00 | +2.8% | 157.19 |
| 12 Oct 2026 | Raymond James | — | 164.00 | — | 151.17 |
| 8 Oct 2026 | RBC Capital Brian Abrahams | Reiterated · Sector Perform | 123.00 → 126.00 | +2.4% | 145.64 |
| 7 Oct 2026 | Truist Financial | Reiterated · Buy | 150.00 → 158.00 | +5.3% | 147.53 |
| 10 Sept 2026 | HSBC Morten Herholdt | Reiterated · Buy | 155.00 → 175.00 | +12.9% | 145.65 |
| 5 Aug 2026 | Truist Financial | — | 157.00 → 150.00 | -4.5% | 132.76 |
| 5 Aug 2026 | RBC Capital | Reiterated · Sector Perform | 120.00 → 123.00 | +2.5% | 135.25 |
| 29 Jul 2026 | Barclays | Reiterated · Equal Weight | 155.00 → 145.00 | -6.5% | 134.32 |
| 27 Jul 2026 | Morgan Stanley | Reiterated · Overweight | 166.00 → 165.00 | -0.6% | 131.23 |
| 21 Jul 2026 | Leerink Partners | Downgraded · Outperform → Market Perform | — | — | — |
| 20 Jul 2026 | Leerink Partners Daina Graybosch | — | 127.00 | — | 133.21 |
| 8 Jul 2026 | Morgan Stanley | Reiterated · Overweight | 168.00 → 166.00 | -1.2% | 136.36 |
| 7 Jul 2026 | RBC Capital Brian Abrahams | Reiterated · Sector Perform | 122.00 → 120.00 | -1.6% | 129.61 |
| 6 Jul 2026 | HSBC Rajesh Kumar | Upgraded · Hold → Buy | 133.00 → 155.00 | +16.5% | 131.27 |
| 1 Jun 2026 | RBC Capital Brian Abrahams | — | 105.00 → 122.00 | +16.2% | 134.43 |
| 20 May 2026 | Maxim Group Michael Okunewitch | Upgraded · Hold → Buy | 165.00 | — | 130.55 |
| 10 May 2026 | Morgan Stanley | — | 175.00 → 168.00 | -4.0% | 131.33 |
| 8 May 2026 | Truist Financial | Reiterated · Buy | 155.00 → 157.00 | +1.3% | 132.03 |
| 10 Apr 2026 | Morgan Stanley | Reiterated · Overweight | 171.00 → 175.00 | +2.3% | 140.34 |
| 8 Apr 2026 | Truist Financial Gregory Renza | — | 162.00 → 155.00 | -4.3% | 141.54 |
| 10 Mar 2026 | Jefferies Akash Tewari | — | 180.00 | — | 146.94 |
| 19 Feb 2026 | Barclays | — | 155.00 | — | 151.12 |
| 19 Feb 2026 | Mizuho Securities | — | 140.00 → 170.00 | +21.4% | 152.74 |
| 18 Feb 2026 | UBS | — | 155.00 → 175.00 | +12.9% | 155.27 |
| 11 Feb 2026 | Scotiabank Louise Chen | Reiterated · Sector Outperform | 177.00 | — | 155.29 |
| 11 Feb 2026 | Bernstein Courtney Breen | — | 135.00 → 160.00 | +18.5% | 155.45 |
| 11 Feb 2026 | Morgan Stanley | — | 150.00 → 171.00 | +14.0% | 155.72 |
| 11 Feb 2026 | Truist Financial | Reiterated · Buy | 152.00 → 162.00 | +6.6% | 155.87 |
| 11 Feb 2026 | Truist Financial | — | 145.00 → 152.00 | +4.8% | 154.69 |
| 11 Feb 2026 | Oppenheimer | — | 132.00 → 165.00 | +25.0% | 153.46 |
| 11 Feb 2026 | Cantor Fitzgerald | Reiterated · Overweight | 135.00 → 155.00 | +14.8% | 147.23 |
| 11 Feb 2026 | Needham Joseph Stringer | Reiterated · Buy | 170.00 | — | 154.09 |
| 11 Feb 2026 | Robert W. Baird | — | 108.00 → 145.00 | +34.3% | 153.89 |
| 11 Feb 2026 | BMO Capital Evan Seigerman | — | 150.00 → 160.00 | +6.7% | 147.23 |
| 11 Feb 2026 | Wells Fargo Mohit Bansal | Reiterated · Overweight | 145.00 → 165.00 | +13.8% | 147.23 |
| 27 Jan 2026 | Truist Financial | Reiterated · Buy | 140.00 → 145.00 | +3.6% | 139.23 |
| 26 Jan 2026 | BMO Capital Evan David Seigerman | — | 135.00 → 150.00 | +11.1% | 137.01 |
| 26 Jan 2026 | UBS | Reiterated · Buy | 145.00 → 155.00 | +6.9% | 136.16 |
| 13 Jan 2026 | Morgan Stanley | Reiterated · Overweight | 151.00 → 150.00 | -0.7% | 122.25 |
| 7 Jan 2026 | UBS Michael Yee | — | 145.00 | — | 121.36 |
| 29 Dec 2025 | Bernstein Courtney Breen | — | 135.00 | — | 124.56 |
| 15 Dec 2025 | Wolfe Research Alexandria Hammond | — | 150.00 | — | 120.41 |
| 12 Dec 2025 | Morgan Stanley | Reiterated · Overweight | 147.00 → 151.00 | +2.7% | 123.21 |
| 10 Dec 2025 | HSBC | — | 133.00 | — | 119.36 |
| 25 Nov 2025 | BMO Capital Evan David Seigerman | — | 135.00 | — | 127.57 |
Gilead Sciences EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Revenue
EPS
Does Gilead Sciences beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 11.0% off the result, either way, and their revenue estimate 3.8%, over the last 12 quarters.
- EPS beats
- 74 / 125
- Revenue beats
- 75 / 118
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +10.6%
- Since
- October 1993
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 29 Oct 2026 | 2.19 | 2.55 | +16.4% | 7.81B | 8.30B | +6.3% |
| Q2 FY2026 | 4 Aug 2026 | -7.25 | -6.75 | +6.9% | 7.40B | 7.80B | +5.5% |
| Q1 FY2026 | 7 May 2026 | 1.91 | 2.03 | +6.3% | 6.91B | 6.96B | +0.7% |
| Q4 FY2025 | 10 Feb 2026 | 1.81 | 1.86 | +2.8% | 7.69B | 7.93B | +3.1% |
| Q3 FY2025 | 30 Oct 2025 | 2.13 | 2.47 | +16.0% | 7.45B | 7.77B | +4.3% |
| Q2 FY2025 | 7 Aug 2025 | 1.96 | 2.01 | +2.6% | 6.98B | 7.08B | +1.4% |
| Q1 FY2025 | 24 Apr 2025 | 1.78 | 1.81 | +1.7% | 6.81B | 6.67B | -2.1% |
| Q4 FY2024 | 11 Feb 2025 | 1.74 | 1.90 | +9.2% | 7.15B | 7.57B | +5.8% |
| Q3 FY2024 | 6 Nov 2024 | 1.53 | 2.02 | +32.0% | 7.02B | 7.55B | +7.5% |
| Q2 FY2024 | 8 Aug 2024 | 1.61 | 2.01 | +24.8% | 6.70B | 6.95B | +3.7% |
| Q1 FY2024 | 25 Apr 2024 | -1.49 | -1.32 | +11.4% | 6.36B | 6.69B | +5.2% |
| Q4 FY2023 | 6 Feb 2024 | 1.76 | 1.72 | -2.3% | 7.10B | 7.12B | +0.2% |
Gilead Sciences stock price 2026–2030: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
If Gilead Sciences's earnings keep growing at the 9.8% a year analysts expect to FY2028, it would earn about 12.99 a share in FY2030. At the P/E it has traded at over the last five years (14.6 to 23.5) that is 190.17 to 304.71 a share, or 239.95 at its average P/E of 18.5. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | -0.85 | -12.42 | -15.67 | -19.90 |
| FY2027 | 10.10 | 147.90 | 186.62 | 236.98 |
| FY2028 | 10.78 | 157.82 | 199.13 | 252.87 |
| FY2029 (extrapolated) | 11.83 | 173.24 | 218.59 | 277.58 |
| FY2030 (extrapolated) | 12.99 | 190.17 | 239.95 | 304.71 |
Each year's EPS is the analysts' consensus to FY2028; the years after grow 9.8% a year (the analysts' growth, at most 15%). Bear, base and bull apply the lowest, average and highest P/E of today and the last five fiscal year ends, leaving out any above 60, the mark of a year of collapsed earnings (14.6, 18.5, 23.5).
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 99.090 | 194.93146Price 99.09244 | +96.7% | |
| 42.225 | 82.9546Price 42.23165 | +96.4% | |
| 186.680 | 360.82271Price 186.68451 | +93.3% | |
| 213.670 | 405.57304Price 213.67507 | +89.8% | |
| 161.160 | 305.51157Price 161.16396 | +89.6% | |
| 160.650 | 300.09225Price 160.65375 | +86.8% | |
| 165.860 | 308.95212Price 165.86442 | +86.3% |
Furthest below the fair value on each stock's page, updated every day.